English  |  正體中文  |  简体中文  |  0  
???header.visitor??? :  51888634    ???header.onlineuser??? :  890
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

"liu c h"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 611-635 of 1570  (63 Page(s) Totally)
<< < 20 21 22 23 24 25 26 27 28 29 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2021-07-03T03:33:26Z Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment Liu C.-H.; Yang S.-S.; Peng C.-Y.; Lin W.-T.; Liu C.-J.; Su T.-H.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:26Z Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals Liu C.-H.; Lee M.-H.; Lin J.-W.; Liu C.-J.; Su T.-H.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:25Z 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population Yu M.-L.; PEI-JER CHEN; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; Liu C.-J.; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L.
臺大學術典藏 2021-07-03T03:33:23Z Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data Hong C.-M.; Liu C.-H.; Su T.-H.; Yang H.-C.; PEI-JER CHEN; Chen Y.-W.; Kao J.-H.; Liu C.-J.
臺大學術典藏 2021-07-03T03:33:23Z 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations Yu M.-L.; PEI-JER CHEN; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; Liu C.-J.; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L.
臺大學術典藏 2021-07-03T03:33:23Z Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer Su T.-H.; Tseng T.-C.; Liu C.-J.; Chou S.-W.; Liu C.-H.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Chen C.-L.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:21Z High risk of clinical relapse in patients with chronic Hepatitis B virus infection after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy Chang W.-Y.; Chiu Y.-C.; Chiu F.-W.; Hsu Y.-C.; Tseng T.-C.; Cheng P.-N.; Yang S.-S.; Liu C.-J.; Su T.-H.; Yang H.-C.; Liu C.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:20Z Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan Liu C.-H.; Su T.-H.; Liu C.-J.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:20Z Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:17Z Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load Tseng T.-C.; Liu C.-J.; Yang W.-T.; Hsu C.-Y.; Hong C.-M.; Su T.-H.; Tsai C.-H.; Chen C.-L.; Yang H.-C.; Liu C.-H.; Chen H.-H.; PEI-JER CHEN; Kao J.-H.
臺大學術典藏 2021-07-02T03:41:50Z Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy Liang C.-C.; Liu C.-H.; Lin Y.-L.; Liu C.-J.; BOR-LUEN CHIANG; Kao J.-H.
臺大學術典藏 2021-07-02T03:41:19Z The KDM4A/KDM4C/NF-κB and WDR5 epigenetic cascade regulates the activation of B cells Hung K.-H.; Woo Y.H.; Lin I.-Y.; Liu C.-H.; Wang L.-C.; Chen H.-Y.; BOR-LUEN CHIANG; Lin K.-I.
臺大學術典藏 2021-06-29T06:28:21Z Cautious application of pleural N-terminal pro-B-type natriuretic peptide in diagnosis of congestive heart failure pleural effusions among critically ill patients Yeh J.-H.; CHUN-TA HUANG; Liu C.-H.; Ruan S.-Y.; Tsai Y.-J.; Chien Y.-C.; Yang C.-Y.; Huang C.-K.; Hsu C.-L.; Kuo L.-C.; Lee P.-L.; Ku S.-C.; Kuo P.-H.; Yu C.-J.; HINT Study Group
臺大學術典藏 2021-06-25T08:10:15Z Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; CHUN-MING HONG; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-06-25T08:10:15Z Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients with Chronic Hepatitis C Virus Infection Liu C.-H.; Chen Y.-S.; Wang S.-S.; Liu C.-J.; Su T.-H.; Yang H.-C.; CHUN-MING HONG; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-06-25T08:10:15Z A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients Liu C.-H.; Liu C.-J.; CHUN-MING HONG; Su T.-H.; Yang H.-C.; Chen K.-M.; Huang Y.-P.; Yeh Y.-M.; Tien H.-L.; Liu Y.-C.; Kao J.-H.; Chen D.-S.; Chen P.-J.
臺大學術典藏 2021-06-25T08:10:14Z Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study Liu C.-H.; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; Liu C.-J.; Liu W.-C.; Su T.-H.; Yang H.-C.; CHUN-MING HONG; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; Kao J.-H.
臺大學術典藏 2021-06-25T08:10:14Z Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection Liu C.-H.; Sun H.-Y.; Liu C.-J.; Sheng W.-H.; Hsieh S.-M.; Lo Y.-C.; Liu W.-C.; Su T.-H.; Yang H.-C.; CHUN-MING HONG; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; Kao J.-H.
臺大學術典藏 2021-06-25T08:10:13Z Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection Liu C.-H.; Su T.-H.; Liu C.-J.; CHUN-MING HONG; Yang H.-C.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-06-25T08:10:13Z Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; CHUN-MING HONG; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-06-25T08:10:13Z NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging Su T.-H.; Liao S.-H.; CHUN-MING HONG; Liu C.-J.; Tseng T.-C.; Liu C.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chen C.-L.; Adhoute X.; Bourlière M.; Kao J.-H.
臺大學術典藏 2021-06-25T08:10:12Z Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data CHUN-MING HONG; Liu C.-H.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen Y.-W.; Kao J.-H.; Liu C.-J.
臺大學術典藏 2021-06-25T08:10:12Z High Level of Hepatitis B Core–Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load Tseng T.-C.; Liu C.-J.; Hsu C.-Y.; CHUN-MING HONG; Su T.-H.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Huang Y.-T.; Fang-Tzu Kuo S.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-06-25T08:10:11Z Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load Tseng T.-C.; Liu C.-J.; Yang W.-T.; Hsu C.-Y.; CHUN-MING HONG; Su T.-H.; Tsai C.-H.; Chen C.-L.; Yang H.-C.; Liu C.-H.; Chen H.-H.; Chen P.-J.; Kao J.-H.
臺大學術典藏 2021-06-25T07:21:55Z Losartan reduces ensuing chronic kidney disease and mortality after acute kidney injury Cheng S.-Y.; Chou Y.-H.; Liao F.-L.; Lin C.-C.; Chang F.-C.; Liu C.-H.; Huang T.-M.; Lai C.-F.; YU-FENG LIN; Wu V.-C.; Chu T.-S.; Wu M.-S.; Lin S.-L.

Showing items 611-635 of 1570  (63 Page(s) Totally)
<< < 20 21 22 23 24 25 26 27 28 29 > >>
View [10|25|50] records per page